CASTLE ROCK, CO–( EMWNews – March 31, 2008) – AspenBio Pharma, Inc. (NASDAQ: APPY), an

emerging bio-pharmaceutical company dedicated to the development of novel

drugs and diagnostics for animals and humans, has appointed Dr. Mark J.

Ratain as a new independent member of its board of directors. His

appointment brings the total number of company directors to six, with four

serving independently.

Dr. Ratain is an accomplished and highly regarded hematologist/oncologist

and clinical pharmacologist. Since 1983, he has been affiliated with the

Department of Medicine at the University of Chicago, where he is currently

the Leon O. Jacobson Professor of Medicine and chairman of the Committee on

Clinical Pharmacology and Pharmacogenomics. He is also the associate

director for clinical sciences at the University of Chicago’s Cancer

Research Center. He serves on committees at Georgetown University and St.

Jude Children’s Research Hospital, and is a member of multiple professional

societies.

Dr. Ratain has authored and co-authored more than 300 articles and book

chapters, and participates in research review for the National Institutes

of Health. He is a past advisor to the Food and Drug Administration, and

was elected in 2007 to the American Association of Physicians.

He has been involved in the development of several anticancer agents, and

was the lead inventor on the FDA-approved UGT1A1 diagnostic to predict

irinotecan therapy, commercialized as a 510(k) device in 2005. He recently

received the Emil J. Freireich Award in Clinical Research from MD Anderson

Cancer Center in Houston.

Dr. Ratain is also a director of DATATRAK International, Inc., a technology

and services company focused on providing a platform of software

applications to the global clinical trials industry. He received his A.B.

Degree in Biochemical Sciences from Harvard University and his M.D. from

the Yale University School of Medicine.

“We are honored and fortunate to have Dr. Ratain join our board,” said Greg

Pusey, AspenBio Pharma’s chairman. “His award-winning expertise and

achievements in the world of medicine substantially enhances our board

leadership. Dr. Ratain joins us at an exciting period in the development of

AspenBio’s appendicitis test and single-chain animal products. We look

forward to benefiting from his extensive experience as we work to bring

these products to market.”

About AspenBio Pharma

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the

discovery; development, manufacture, and marketing of novel proprietary

products, including those that enhance the reproductive efficiency of

animals and that have large worldwide market potential. The company was

originally formed to produce purified proteins for diagnostic applications

and has become a leading supplier of human hormones to many of the nation’s

largest medical diagnostic companies and research institutions. The company

has successfully leveraged this foundational science and technology

expertise to rapidly develop an enviable late-stage pipeline of several

novel reproduction hormone analogs for wide-ranging therapeutic use

initially in bovine and equine species. AspenBio Pharma continues to

advance the development and testing of its two first-generation blood-based

human diagnostic tests designed to rapidly help diagnose or rule out

appendicitis in patients complaining of abdominal pain. For more

information, go to www.aspenbiopharma.com.